(Q40308157)

English

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b,

scientific article published on March 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hans-Jürgen Stellbrink

9

object named as

Hans-Jürgen Stellbrink

0 references

Danielle P Porter

13

object named as

Danielle Porter

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Jean-Michel Molina

10

object named as

Jean-Michel Molina

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Edwin DeJesus

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Moti Ramgopal

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Gordon Crofoot

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Peter Ruane

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Anthony LaMarca

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Anthony Mills

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Claudia T Martorell

7

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Joseph de Wet

8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Hans-Jürgen Stellbrink

9

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Frank A Post

11

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Ignacio Pérez Valero

12

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

YaPei Liu

14

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Andrew Cheng

15

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Erin Quirk

16

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Devi SenGupta

17

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Huyen Cao

18

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

publication date

1 March 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

The lancet. HIV

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

e205-e213

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz: a decade of clinical experience in the treatment of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind,

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The frequency and reasons for antiretroviral switching with specific antiretroviral associations: the SWITCH study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Test-based exact confidence intervals for the difference of two binomial proportions

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A generalized least significant change for individuals measured on different DXA systems

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The fallback procedure for evaluating a single family of hypotheses.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Progressive renal tubular dysfunction associated with long-term use of tenofovir DF.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3018%2817%2930032-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3018(17)30032-2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40308157&oldid=1586204682"